CredoScientia - Bibliothèque

Importance of optimizing duration of adjuvant immune checkpoint inhibitor therapy to treat postoperative hepatocellular carcinoma after conversion therapy: a case report.

Patients with hepatocellular carcinoma at high risk of recurrence after hepatic resection or local ablation often undergo adjuvant immunotherapy with immune checkpoint inhibitors for 1 year in randomi…

Thérapies de Conversion

Li, J. R., Yang, D. L., Wang, J. M., Tian, W., Wei, W., Luo, C. P., Qi, L. N., Ma, L., & Zhong, J. H. (2023). Importance of optimizing duration of adjuvant immune checkpoint inhibitor therapy to treat postoperative hepatocellular carcinoma after conversion therapy: a case report.. J Surg Case Rep, 2023(11), rjad610. https://doi.org/10.1093/jscr/rjad610

01/11/2023 Lire →

One case of advanced metastatic gastric cancer achieving pathologic complete response after conversion therapy.

Thérapies de Conversion

Shuang, Y., Wang, F., Chen, S., & Sun, F. (2023). One case of advanced metastatic gastric cancer achieving pathologic complete response after conversion therapy.. Asian J Surg, 46(11), 5174-5175. https://doi.org/10.1016/j.asjsur.2023.07.010

01/11/2023 Lire →

Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study.

BACKGROUND: The treatment efficacy of transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC) for huge single hepatocellular carcinoma (HCC) has not been fully documen…

Thérapies de Conversion

Deng, M., Cai, H., He, B., Guan, R., Lee, C., & Guo, R. (2023). Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study.. Int J Surg, 109(11), 3303-3311. https://doi.org/10.1097/JS9.0000000000000654

01/11/2023 Lire →

Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (L-ALPPS) After Conversion Therapy for BCLC-B Hepatocellular Carcinoma: A Video Article.

BACKGROUND: Despite the ALPPS technique remains a controversy, various ALPPS techniques have made many attempts. This video discusses the technical tips for L-ALPPS after conversion therapy.METHODS: A…

Thérapies de Conversion

Wang, J., Xu, J., & Liu, Z. (2023). Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (L-ALPPS) After Conversion Therapy for BCLC-B Hepatocellular Carcinoma: A Video Article.. Ann Surg Oncol, 30(12), 7360-7361. https://doi.org/10.1245/s10434-023-13946-x

01/11/2023 Lire →

Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.

This retrospective multicenter study analyzed 244 patients with unresectable hepatocellular carcinoma treated with lenvatinib (LEN) and atezolizumab + bevacizumab (Atezo + Bev) to examine the characte…

Thérapies de Conversion

Tomonari, T., Tani, J., Sato, Y., Tanaka, H., Tanaka, T., Taniguchi, T., Kawano, Y., Morishita, A., Okamoto, K., Sogabe, M., Miyamoto, H., Masaki, T., & Takayama, T. (2023). Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.. Cancers (Basel), 15(21). https://doi.org/10.3390/cancers15215221

30/10/2023 Lire →

The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials.

BACKGROUND: Adding anti-epidermal growth factor receptor (anti-EGFR) target agents to conversion therapy may improve the resection rates and survival of patients with potentially resectable metastatic…

Thérapies de Conversion

Wang, Y., Li, X., Huang, T., Wang, D., He, Y., Wei, M., Chen, Y., Zheng, M., Shi, Y., & Zhang, J. (2023). The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials.. World J Surg Oncol, 21(1), 340. https://doi.org/10.1186/s12957-023-03222-3

26/10/2023 Lire →

Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy.

Thérapies de Conversion

Zhang, Z., & Zhang, W. (2023). Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy.. Hepatobiliary Surg Nutr, 12(5), 772-775. https://doi.org/10.21037/hbsn-23-352

01/10/2023 Lire →

Dual transformation therapy for giant hepatocellular carcinoma: Two case reports and review of literature.

BACKGROUND: In the translational therapy of giant hepatocellular carcinoma (HCC), hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors (TK…

Thérapies de Conversion

Gao, Q., Zhu, G. Z., Han, C. Y., Ye, X. P., Huang, H. S., Mo, S. T., & Peng, T. (2023). Dual transformation therapy for giant hepatocellular carcinoma: Two case reports and review of literature.. World J Gastrointest Surg, 15(9), 2089-2097. https://doi.org/10.4240/wjgs.v15.i9.2089

27/09/2023 Lire →

Radio-granular hydrogels for image-guided tumor brachytherapy.

Thérapies de Conversion

Shao, S., Xu, X., Lin, G., & Liu, G. (2023). Radio-granular hydrogels for image-guided tumor brachytherapy.. ILIVER, 2(3), 177-179. https://doi.org/10.1016/j.iliver.2023.08.006

01/09/2023 Lire →

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.

BACKGROUND: Over 70% of the patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage and lose the opportunity for radical surgery. Combination therapy of tyrosine kinase inhibit…

Thérapies de Conversion

Zhang, W., Tong, S., Hu, B., Wan, T., Tang, H., Zhao, F., Jiao, T., Li, J., Zhang, Z., Cai, J., Ye, H., Wang, Z., Chen, S., Wang, Y., Li, X., Wang, F., Cao, J., Tian, L., Zhao, X., … Lu, S. (2023). Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.. J Immunother Cancer, 11(9). https://doi.org/10.1136/jitc-2023-007366

01/09/2023 Lire →

Evaluating Tislelizumab, Lenvatinib, and FOLFOX4-HAIC as a Conversion Therapy for Unresectable Hepatocellular Carcinoma.

BACKGROUND AND AIMS: Conversion therapy downstages tumors and renders patients with unresectable hepatocellular carcinoma (HCC) eligible for radical resection. This study aimed to evaluate the efficac…

Thérapies de Conversion

Tan, K., He, X., Yuan, H., Zhao, S., Gong, C., Zhao, Y., Nan, H., Zang, L., Luo, Z., & Du, X. (2023). Evaluating Tislelizumab, Lenvatinib, and FOLFOX4-HAIC as a Conversion Therapy for Unresectable Hepatocellular Carcinoma.. ILIVER, 2(3), 163-169. https://doi.org/10.1016/j.iliver.2023.08.003

01/09/2023 Lire →

Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.

PURPOSE: Primary tumour resection (PTR) is still a selection for patients with low tumour burden and good condition, especially with conversion therapy purpose for colorectal liver-limited metastases …

Thérapies de Conversion

Lin, Q., Ding, K., Zhao, R., Wang, H., Wei, Y., Ren, L., Ye, Q., Cui, Y., He, G., Tang, W., Feng, Q., Zhu, D., Chang, W., Wang, X., Liang, L., Zhou, G., Liang, F., Ye, F., Wang, J., … Xu, J. (2023). Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.. Eur J Cancer, 191, 112961. https://doi.org/10.1016/j.ejca.2023.112961

01/09/2023 Lire →